Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
AbbVie Files Skyrizi for Pediatric Dosage in Japan
AbbVie said on October 29 that it has filed an application in Japan to add a pediatric dosage and administration for the psoriasis indications of its IL-23 inhibitor Skyrizi (risankizumab).The filing seeks to broaden the label of Skyrizi to pediatric…
To read the full story
Related Article
BUSINESS
- Eisai Maps Out Next-Gen Alzheimer’s Strategy beyond Leqembi
August 18, 2026
- Enhertu Hits PIII Primary Goal in 1st-Line HER2-Mutant NSCLC
August 18, 2026
- Enhertu Combo Scores China Nod in 1st-Line HER2 Breast Cancer
August 18, 2026
- Santen Releases Glaucoma Drug Rhopressa in Japan
August 18, 2026
- Yaz AGs Now Available in Japan, Hisamitsu Handling Distribution
August 18, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…